Related Experiment Video
Updated: Apr 30, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Pharmaceuticalisation and ethical review in South Asia: issues of scope and authority for practitioners and policy
Bob Simpson1, Rekha Khatri2, Deapica Ravindran3
1Department of Anthropology, Durham University, Dawson Building, Lower Mountjoy, Stockton Rd., Durham DH1 3LE, UK.
Abstract:
Ethical review by expert committee continues to be the first line of defence when it comes to protecting human subjects recruited into clinical trials. Drawing on a large scale study of biomedical experimentation across South Asia, and specifically on interviews with 24 ethical review committee [ERC] members across India, Sri Lanka and Nepal, this article identifies some of the tensions that emerge for ERC members as the capacity to conduct credible ethical review of clinical trials is developed across the region. The article draws attention to fundamental issues of scope and authority in the operation of ethical review. On the one hand, ERC members experience a powerful pull towards harmonisation and a strong alignment with international standards deemed necessary for the global pharmaceutical assemblage to consolidate and extend. On the other hand, they must deal with what is in effect the double jeopardy of ethical review in developing world contexts. ERC members must undertake review but are frequently made aware of their responsibility to protect interests that go beyond the 'human subject' and into the realms of development and national interest [for example, in relation to literacy and informed consent]. These dilemmas are indicative of broader questions about where ethical review sits in institutional terms and how it might develop to best ensure improved human subject protection given growth of industry-led research.
Related Concept Videos
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Regulation
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Bioavailability Study Design: Healthy Subjects Versus Patients
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

